TALLAHASSEE, Fla., Dec. 15, 2022 /PRNewswire/ — PRESS RELEASE — Trulieve Cannabis Corp., a U.S. cannabis company, announced their partnership with California-based Connected Cannabis and AlienLabs. As part of the announcement, Trulieve is the exclusive provider of Connected Branded products throughout Florida.

“Trulieve consistently seeks ways to introduce new products and better serve our patients,” said Kim Rivers, CEO of Trulieve. “Connected and AlienLabs represent a portfolio of top-shelf strains that have benefited medical patients in other states, and we’re now excited to exclusively offer these products exclusively in Florida.”

AlienLabs is well-known for its flower strains with a focus on top-shelf, exotic, indoor cannabis. As one of the first California cannabis brands, AlienLabs has established a reputation for pushing quality to new heights in cannabis and takes pride in creating new, unique strains with a menu where each strain is distinct. Two strains, Xeno and Kryptochronic, will be available at select Trulieve Florida locations beginning Dec. 15.

Connected Cannabis offers high-quality cannabis by developing different cultivation techniques to create the strains they are now best known for in the California market. Three strains, El Jefe, Gelonade, and Nightshade, will be available at select Trulieve Florida locations beginning Dec. 20.

As the state’s leading medical cannabis provider, Trulieve patients across Florida can choose from the largest selection of THC and CBD products available in a variety of consumption methods, including smokable flower, concentrates, edibles, capsules, syringes, tinctures, topical creams, vaporizers, and more.

For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook.

More information on Connected can be found at connectedcannabisco.com or on Instagram @connected.california. Learn more about AlienLabs at alienlabs.org or on Instagram @alienlabs.



Read the full article here

Share.
Leave A Reply

Exit mobile version